Vanda Pharmaceuticals
VNDA
177 hedge funds and large institutions have $396M invested in Vanda Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 67 increasing their positions, 61 reducing their positions, and 32 closing their positions.
4.5% more ownership
Funds ownership: 98.05% → 102.55% (+4.5%)
10% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 61
2% more capital invested
Capital invested by funds: $389M → $396M (+$6.97M)
7% less funds holding
Funds holding: 190 → 177 (-13)
38% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 32
48% less call options, than puts
Call options by funds: $17K | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$9.46M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.79M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$5.35M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$3.98M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9.78M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$4.86M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$4.25M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$2.32M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.16M |
VNDA Hedge Fund Activity: Q1 2023 in Review
177 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2023, worth a combined $396M — up 1.8% from $389M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of VNDA and 20 opened new positions — a net loss of 12 holders — while 61 trimmed existing stakes and 67 added.
The largest buyer was Bank of America, adding an estimated $9.46M. The largest seller was Macquarie Group, exiting entirely with an estimated $9.78M sold.
- 177 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2023, down from 190 in Q4 2022.
- Funds reported $396M of Vanda Pharmaceuticals stock for Q1 2023, up 1.8% quarter-over-quarter.
- 20 funds opened new Vanda Pharmaceuticals positions in Q1 2023 and 32 closed out, a net change of -12 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2023 was Bank of America, an estimated $9.46M added.
- The largest Vanda Pharmaceuticals seller in Q1 2023 was Macquarie Group, an estimated $9.78M sold.
Based on aggregated 13F filings for Q1 2023.